Ovarian Cancer

Lyndsay J. Willmott, MD, highlights the FDA-approved PARP inhibitors for ovarian cancer and how these approvals have impacted clinical practice.

Mike Janicek, MD sheds light on why physicians are slow to educate patients on testing, the detection of genes aside from BRCA1/2, and the lesser-known benefits of getting genetic testing early on in a diagnosis.

Dana Chase, MD, expands on the pivotal clinical trials, managing toxicities, and the questions researchers still need to answer regarding bevacizumab for patients with ovarian cancer.

Heather Dalton, MD, discusses the first-line treatment options currently available for patients with ovarian cancer, pivotal data that have solidified standard approaches, and why chemotherapy will likely always remain critical in the ovarian cancer sphere.

Shana Wingo, MD, explains how surgical approaches have evolved in ovarian cancer.

Treatment with the RAF dimer inhibitor BGB-283 led to clinical benefit for patients with BRAF V600-mutated melanoma, papillary thyroid cancer, and ovarian cancer.

Ursula A. Matulonis, MD, discusses the latest regulatory advances with PARP inhibitors and their continued growth in the treatment of patients with ovarian cancer.

Paul Pharoah, MD, PhD, discusses the significance of his research in ovarian cancer and the potential for translating genetic discoveries into meaningful clinical benefits.

The FDA has granted a priority review to a new drug application for olaparib (Lynparza) as a maintenance therapy in relapsed patients with platinum-sensitive ovarian cancer, according to AstraZeneca, the manufacturer of the PARP inhibitor.

The FDA has approved the PARP inhibitor niraparib (Zejula) for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.

Emma Barber, MD, discusses the impact of neoadjuvant chemotherapy on readmission rates, and how the goal of lowering readmission rates in ovarian cancer may not always align with optimizing long-term outcomes.

Elizabeth Swisher, MD, professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses the results of the ARIEL2 trial in patients in patients with relapsed, platinum-sensitive, high-grade ovarian carcinoma with a germline or somatic BRCA mutation.

Steven J. Skates, PhD, discusses the standard of care, risk-reducing salpingo-oophorectomy, for women with ovarian cancer and highlights that the best option for women who choose to postpone surgery is frequent CA125 testing with the Risk of Ovarian Cancer Algorithm.

David M. Gershenson, MD, discusses the results for a retrospective study of patients with stage II to IV low-grade serous carcinoma of the ovary or peritoneum and the next steps going forward.

Kathleen N. Moore, MD, assistant professor, The Stephenson Cancer Center, The University of Oklahoma, discusses the international, randomized phase III NOVA trial for recurrent platinum-sensitive ovarian cancer.

Maintenance chemotherapy after debulking surgery and adjuvant platinum-based chemotherapy did not improve overall survival rates in women with ovarian cancer who had achieved complete remission.

Maintenance therapy with olaparib showed a 70% reduction in the risk of progression or death compared with placebo for patients with platinum-sensitive, relapsed, BRCA-mutant ovarian cancer.

Christina M. Annunziata, MD, PhD, head, Translational Genomics Section, National Cancer Institute, discusses the phase II/III study of olaparib (Lynparza) and cediranib for patients with platinum-resistant ovarian cancer.

Treatment with a carboplatin desensitization regimen led to improved overall survival in patients with BRCA-proficient ovarian cancer.

The PARP inhibitor niraparib improved progression-free survival in patients with recurrent, platinum-sensitive, high-grade ovarian cancer, regardless of BRCA status, according to a review of the phase III ENGOT-OV16/NOVA trial presented at the 2017 Society of Gynecologic Oncology Annual Meeting.

Jubilee Brown, MD, obstetrician-gynecologist, Levine Cancer Institute, Carolinas HealthCare System, discusses genetic counseling for patients with breast and ovarian cancer.

Ursula A. Matulonis, MD, professor of Medicine, Harvard Medical School, medical director of Gynecologic Oncology, Dana-Farber Cancer Institute, discusses the secondary efficacy results of the NOVA trial, which examines niraparib maintenance therapy for patients with ovarian cancer.

Hypermethylation of 2 wild-type tumor-associated genes increased ovarian cancer responsiveness to the PARP inhibitor rucaparib (Rubraca).

Emma Barber, MD, UNC Department of Obstetrics and Gynecology, UNC School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses surgical readmission and survival in patients with ovarian cancer.

Elizabeth Swisher, MD, professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses next steps regarding treatments for patients with ovarian cancer.